QBM 076
Alternative Names: QBM-076Latest Information Update: 30 Oct 2021
At a glance
- Originator Novartis
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease
Most Recent Events
- 29 Sep 2015 Discontinued - Phase-II for Chronic obstructive pulmonary disease in USA, Germany, Hungary, Netherlands, Romania and United Kingdom (PO)
- 24 Oct 2013 Clinical trials in Chronic obstructive pulmonary disease in United Kingdom (PO)
- 24 Oct 2013 Clinical trials in Chronic obstructive pulmonary disease in Germany (PO)